WHO COVID-19 Trial drops hydroxychloroquine, HIV combo lopinavir/ritonavir after 'lack of evidence' in hospitalised patients
Hydroxychloroquine and lopinavir/ritonavir produced little or no reduction in the mortality in hospitalized patients compared to standard of care, the trial concluded.
The World Health Organisation has pulled the steroid drug hydroxychloroquine and HIV treatment combination lopinavir/ritonavir from their ongoing COVID-19 Solidarity trials, after a recommendation from the international Steering Committee advising the same. The Solidarity Trial, established by WHO, is working to find a working treatment in hospitalized patients.
The Committee's recommendation comes after mounting evidence comparing hydroxychloroquine and lopinavir/ritonavir with standard-of-care treatment from the Trial's interim results, WHO said in a press release. The evidence from all trials was reviewed and summarised at the 1-2 July WHO Summit on COVID-19 research and innovation, the release added.
Hydroxychloroquine and lopinavir/ritonavir produced little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care, the trial concluded.
WHO accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and the lopinavir/ritonavir arms.
— World Health Organization (WHO) (@WHO) July 4, 2020
However, some safety information was compiled based on clinical findings in the associated Discovery trial, an arm of the Solidarity trial. WHO said that these will be reported in an upcoming peer-reviewed publication. The interim Solidarity results are now being readied for peer-reviewed publication, it added.
The decision only applies to WHO's Solidarity trial in hospitalized patients, and doesn't rule out its use in other studies to treat non-hospitalized patients, or as a pre- or post-exposure preventive treatment for COVID-19, the release clarified.
Hydroxychloroquine was shown in laboratory experiments earlier this year to be able to block the SARS-CoV-2 virus that causes COVID-19, but this effect has not been replicated in rigorous trials in people.
Post-COVID care: Take it easy on daily chores; try these techniques to manage fatigue, conserve energy
Given what we know about COVID-19 and the immense impact it has on patients’ lives, the road to recovery is expected to be more intense
COVID-19 herd immunity will take time, easier to achieve with vaccine, says WHO’s Soumya Swaminathan
The chief scientist at the global health body said that more waves of coronavirus would be required to get to a stage of natural immunity
Evidence suggests younger children don’t spread the disease easily but kids aged 10 and up transmit as easily as adults.